reading some of the presentation summaries, i understand the complexity of the situation... many big players will be there...
unless the status has changed since june 2 pr, bavi is still in the mix... whether it is a factor remains to be seen... from what i can gather the scientists seem to be focused on what works where and why... personalized medicine....
here are some summaries...
Edward Cha, M.D., Ph.D., Associate Medical Director, Cancer Immunotherapy Franchise, Genentech
Although targeted inhibition of the PD-L1 pathway enhances anti-tumor immunity, not all patients achieve benefit from single-agent immunotherapies. Determining and prioritizing effective combinations will rely on further understanding of the mechanisms that drive immune resistance across indications and individual patients.
David Kaufman, Ph.D., Executive Director, Clinical Oncology, Merck Research Laboratories
A variety of other agents may have additive or synergistic activity in combination with PD-1 checkpoint blockade. As such regimens advance, it will be critically important to understand how to direct the right combinations to patients who stand to benefit most from them. Next-generation biomarkers are beginning to provide insight into fundamental aspects of tumor cell and immune biology that are relevant for a precision medicine approach to cancer immunotherapy combinations.
Cancer Immunotherapy: Immunomodulatory Approaches Beyond PD-1
Andrea_van_ElsasAndrea van Elsas, Ph.D., CSO, Aduro Biotech Europe, The Netherlands
T cell checkpoint inhibitors set a clinical paradigm providing significant benefit to patients diagnosed with advanced cancer. Despite success, the majority of patients do not respond to PD-1, PD-L1 or CTLA-4 blockade. Raising the number of patients benefiting from cancer immunotherapy requires novel therapeutic approaches aimed at these non-responders, for instance using novel immunomodulatory antibodies and combination with active immunization.
Market Data 
Markets 
AI
